{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HBV",
    "query": {
      "intervention": "HBV"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 327,
    "total_pages": 33,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HBV&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T12:46:25.951Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01859884",
      "title": "Optimizing Kidney Transplant Informed Consent",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "End-stage Kidney Disease"
      ],
      "interventions": [
        {
          "name": "Inform Me: web-based education tool",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 288,
      "start_date": "2013-10",
      "completion_date": "2015-11",
      "has_results": false,
      "last_update_posted_date": "2015-11-20",
      "last_synced_at": "2026-09-03T12:46:25.951Z",
      "location_count": 2,
      "location_summary": "Birmingham, Alabama • Chicago, Illinois",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01859884"
    },
    {
      "nct_id": "NCT00985426",
      "title": "Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "HEPLISAV-B",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Engerix-B",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Dynavax Technologies Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 521,
      "start_date": "2009-09",
      "completion_date": "2012-01",
      "has_results": true,
      "last_update_posted_date": "2021-05-19",
      "last_synced_at": "2026-09-03T12:46:25.951Z",
      "location_count": 1,
      "location_summary": "Norfolk, Virginia",
      "locations": [
        {
          "city": "Norfolk",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00985426"
    },
    {
      "nct_id": "NCT03300414",
      "title": "Biologic Basis of Liver Cancer From Chronic Hepatitis B",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hepatocellular Carcinoma",
        "Hepatitis B, Chronic"
      ],
      "interventions": [
        {
          "name": "One time blood draw",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2017-03-20",
      "completion_date": "2018-12-14",
      "has_results": false,
      "last_update_posted_date": "2019-04-11",
      "last_synced_at": "2026-09-03T12:46:25.951Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03300414"
    },
    {
      "nct_id": "NCT00936715",
      "title": "Rollover Protocol Continued Access to Emtricitabine/Tenofovir Disoproxil Fumarate for Adults in United States",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Hepatitis B"
      ],
      "interventions": [
        {
          "name": "FTC/TDF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 24,
      "start_date": "2009-08",
      "completion_date": "2015-11",
      "has_results": true,
      "last_update_posted_date": "2017-06-02",
      "last_synced_at": "2026-09-03T12:46:25.951Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • San Francisco, California • Miami, Florida + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00936715"
    },
    {
      "nct_id": "NCT03547908",
      "title": "Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV-1/HBV Co-Infection"
      ],
      "interventions": [
        {
          "name": "B/F/TAF",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match DTG",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match F/TDF",
          "type": "DRUG"
        },
        {
          "name": "DTG",
          "type": "DRUG"
        },
        {
          "name": "F/TDF",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match B/F/TAF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 244,
      "start_date": "2018-05-30",
      "completion_date": "2024-03-07",
      "has_results": true,
      "last_update_posted_date": "2025-03-19",
      "last_synced_at": "2026-09-03T12:46:25.951Z",
      "location_count": 4,
      "location_summary": "Ft. Pierce, Florida • West Palm Beach, Florida • Berkley, Michigan + 1 more",
      "locations": [
        {
          "city": "Ft. Pierce",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Berkley",
          "state": "Michigan"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03547908"
    },
    {
      "nct_id": "NCT01282762",
      "title": "Long-Term Study on Safety and Immunogenicity of HEPLISAV™ and Engerix-B® in Adults With Chronic Kidney Disease",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "HEPLISAV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Engerix-B",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Dynavax Technologies Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 147,
      "start_date": "2010-12",
      "completion_date": "2013-08",
      "has_results": false,
      "last_update_posted_date": "2019-03-20",
      "last_synced_at": "2026-09-03T12:46:25.951Z",
      "location_count": 1,
      "location_summary": "Norfolk, Virginia",
      "locations": [
        {
          "city": "Norfolk",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01282762"
    },
    {
      "nct_id": "NCT00035789",
      "title": "A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Negative for Hepatitis B e Antigen",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Hepatitis B"
      ],
      "interventions": [
        {
          "name": "Entecavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2001-11",
      "completion_date": "2005-05",
      "has_results": false,
      "last_update_posted_date": "2011-04-14",
      "last_synced_at": "2026-09-03T12:46:25.951Z",
      "location_count": 31,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 28 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00035789"
    },
    {
      "nct_id": "NCT00423891",
      "title": "A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis B, Chronic"
      ],
      "interventions": [
        {
          "name": "Entecavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "2 Years to 18 Years"
      },
      "enrollment_count": 64,
      "start_date": "2007-06-30",
      "completion_date": "2017-09-04",
      "has_results": true,
      "last_update_posted_date": "2018-05-02",
      "last_synced_at": "2026-09-03T12:46:25.951Z",
      "location_count": 9,
      "location_summary": "San Francisco, California • Hartford, Connecticut • Gainesville, Florida + 6 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00423891"
    },
    {
      "nct_id": "NCT00144313",
      "title": "VaxTeen Hepatitis B Vaccine Booster Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hepatitis"
      ],
      "interventions": [
        {
          "name": "hepatitis B vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Centers for Disease Control and Prevention",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "13 Years to 16 Years"
      },
      "enrollment_count": 60,
      "start_date": "2005-08",
      "completion_date": "2006-01",
      "has_results": false,
      "last_update_posted_date": "2007-09-21",
      "last_synced_at": "2026-09-03T12:46:25.951Z",
      "location_count": 1,
      "location_summary": "Anchorage, Alaska",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00144313"
    },
    {
      "nct_id": "NCT02096263",
      "title": "Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Poliomyelitis",
        "Diphtheria",
        "Haemophilus Influenzae Type b",
        "Tetanus",
        "Acellular Pertussis",
        "Hepatitis B"
      ],
      "interventions": [
        {
          "name": "Infanrix hexa",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pediarix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ActHIB",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pentacel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Engerix-B",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Infanrix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hiberix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prevnar13",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rotarix",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Weeks",
        "maximum_age": "12 Weeks",
        "sex": "ALL",
        "summary": "6 Weeks to 12 Weeks"
      },
      "enrollment_count": 585,
      "start_date": "2014-04-16",
      "completion_date": "2015-11-13",
      "has_results": true,
      "last_update_posted_date": "2019-11-27",
      "last_synced_at": "2026-09-03T12:46:25.951Z",
      "location_count": 43,
      "location_summary": "Tucson, Arizona • Fayetteville, Arkansas • Anaheim, California + 38 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Daly City",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02096263"
    }
  ]
}